93 related articles for article (PubMed ID: 2137405)
21. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins.
Bhathena RK; Anklesaria BS; Ganatra AM; Pinto R
Br J Clin Pharmacol; 1998 Feb; 45(2):170-2. PubMed ID: 9491833
[TBL] [Abstract][Full Text] [Related]
22. Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate.
Fåhraeus L; Sydsjö A; Wallentin L
Fertil Steril; 1986 Apr; 45(4):503-6. PubMed ID: 2937657
[TBL] [Abstract][Full Text] [Related]
23. Effect of large-dose progesterone on plasma levels of lipids, lipoproteins and apolipoproteins in males.
Chen JJ; Berlin FS; Margolis S
J Endocrinol Invest; 1986 Aug; 9(4):281-5. PubMed ID: 2946755
[TBL] [Abstract][Full Text] [Related]
24. Hormone replacement therapy and lipoprotein changes during early menopause.
Egeland GM; Kuller LH; Matthews KA; Kelsey SF; Cauley J; Guzick D
Obstet Gynecol; 1990 Nov; 76(5 Pt 1):776-82. PubMed ID: 2170887
[TBL] [Abstract][Full Text] [Related]
25. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
[TBL] [Abstract][Full Text] [Related]
26. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
[TBL] [Abstract][Full Text] [Related]
27. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.
Draper BH; Morroni C; Hoffman M; Smit J; Beksinska M; Hapgood J; Van der Merwe L
Cochrane Database Syst Rev; 2006 Jul; (3):CD005214. PubMed ID: 16856087
[TBL] [Abstract][Full Text] [Related]
28. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
[TBL] [Abstract][Full Text] [Related]
29. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
Soufir JC; Jouannet P; Marson J; Soumah A
Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
[TBL] [Abstract][Full Text] [Related]
30. Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women.
Barnes RB; Roy S; Lobo RA
Obstet Gynecol; 1985 Aug; 66(2):216-9. PubMed ID: 2991832
[TBL] [Abstract][Full Text] [Related]
31. Circulating lipid and lipoprotein concentrations during danazol and high-dose medroxyprogesterone acetate therapy of endometriosis.
Telimaa S; Penttilä I; Puolakka J; Rönnberg L; Kauppila A
Fertil Steril; 1989 Jul; 52(1):31-5. PubMed ID: 2526031
[TBL] [Abstract][Full Text] [Related]
32. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
Akerlund M; Almström E; Högstedt S; Nabrink M
Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
[TBL] [Abstract][Full Text] [Related]
33. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial.
Anawalt BD; Amory JK; Herbst KL; Coviello AD; Page ST; Bremner WJ; Matsumoto AM
J Androl; 2005; 26(3):405-13. PubMed ID: 15867009
[TBL] [Abstract][Full Text] [Related]
34. The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. I. Uniform dosage levels.
Frick J; Bartsch G; Weiske WH
Contraception; 1977 Jun; 15(6):649-68. PubMed ID: 891192
[TBL] [Abstract][Full Text] [Related]
35. [Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors].
Wander HE; Teichmann AT; Cremer P; Wieland H; Kruse B; Nagel GA; Kuhn W; Seidel D
Onkologie; 1985 Apr; 8(2):88-92. PubMed ID: 3158861
[TBL] [Abstract][Full Text] [Related]
36. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
[TBL] [Abstract][Full Text] [Related]
37. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
Hirvonen E; Mälkönen M; Manninen V
N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
[TBL] [Abstract][Full Text] [Related]
38. Bone density in long term users of depot medroxyprogesterone acetate.
Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
[TBL] [Abstract][Full Text] [Related]
39. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W
Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
[TBL] [Abstract][Full Text] [Related]
40. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
